



(51) International Patent Classification:

A01N 47/06 (2006.01) A61K 47/44 (2006.01)
A61K 31/265 (2006.01)

(21) International Application Number:

PCT/US2012/040930

(22) International Filing Date:

5 June 2012 (05.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/493,827 6 June 2011 (06.06.2011) US
61/496,367 13 June 2011 (13.06.2011) US

(71) Applicant (for all designated States except US): **ARBOR THERAPEUTICS, LLC** [US/US]; 147 County Road 245, Etta, MS 38627-9519 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MCCHESNEY, James, D.** [US/US]; c/o Arbor Therapeutics, LLC, 147 County Road 245, Etta, MS 38627-9519 (US). **HENRI, John, T.** [US/US]; c/o Arbor Therapeutics, LLC, 147 County Road 245, Etta, MS 38627-9519 (US). **VEN-KATARAMAN, Sylesh, Kumar** [IN/US]; c/o Arbor Therapeutics, LLC, 147 County Road 245, Etta, MS 38627-9519 (US). **GUNDLURU, Mahesh, Kumar** [IN/US]; c/o Arbor Therapeutics, LLC, 147 County Road 245, Etta, MS 38627-9519 (US).

(74) Agents: **NGUYEN, Sam, L.** et al.; Hamilton, Desantis & Cha LLP, 3239 El Camino Real, Suite 220, Palo Alto, CA 94306 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ACID-LABILE LIPOPHILIC PRODRUGS OF CANCER CHEMOTHERAPEUTIC AGENTS




Figure 1: ART 273 Added to Mouse Plasma

(57) Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.